SOLV Q2 Deep Dive: Portfolio Restructuring and ERP Transition Shape Outlook

Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was 33.8% above analysts’ consensus estimates.